Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists.
A 72-year-old male with a 4-year history of TNFalpha antagonist therapy (infliximab and etanercept) for ankylosing spondylitis was diagnosed with breast cancer. He had a family history of breast cancer. The low incidence and considerable severity of breast cancer in males, genetic risk factors, and potential role for TNFalpha antagonist therapy are discussed.
El Mansouri
Laila
L
Service de Rhumatologie, CHU Rennes, France. la_mansouri1@yahoo.fr
Couchouron
Tifenn
T
Le Roux
Guillaume
G
Dugast
Catherine
C
Burtin
Françoise
F
Albert
Jean-David
JD
Perdriger
Aleth
A
Hassouni
Najia Hajjaj
NH
Chalès
Gérard
G
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018567:Breast Neoplasms, Male / Q000175:diagnosis* / Q000235:genetics / Q000503:physiopathology; D000068800:Etanercept; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012307:Risk Factors; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept